<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies have shown that Janus tyrosine kinase 2 (JAK2) V617F mutation is found in nearly <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) and underlie the basis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> molecular pathogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>Moreover, JAK2 V617F patients with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET) have been found to have some clinical features similar to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To determine whether the same is true in a different Chinese patient population, we employed Allele-specific polymerase chain reaction in combination with sequence analysis to investigate the point mutation in a series of Chinese patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 99 Chinese <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> patients and 120 additional patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> were studied </plain></SENT>
<SENT sid="4" pm="."><plain>The V617F mutation was detected in genomic DNA of peripheral blood samples of 16 of 23 PV patients (69.6%), 21 of 45 ET patients (46.7%) and 3 of 8 patients with idiopathic <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (37.5%) </plain></SENT>
<SENT sid="5" pm="."><plain>There were striking differences in clinical features such as <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, hematocrit and neutrophils percentages between V617F positive and negative patients with ET </plain></SENT>
<SENT sid="6" pm="."><plain>Hence, our data support the idea that JAK2 V617F mutation divides ET patients into two subtypes, with the V617F positive group showing phenotypic similar to that of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> </plain></SENT>
</text></document>